Dr Rajashree Devarakonda | Pharma Bio World | 16 July 2013
India was considered as one of the hubs for conducting major global multinational clinical trials. It still has the potential to establish itself as a hub for global Clinical Trials (CTs). There are several reasons to it, including but not limited to – a large treatment naïve population with diversity in the gene pool with a range of illnesses, many easily accessible tertiary care hospitals, relatively lower cost of clinical trials compared to the western countries, high enrolment rates, good patient compliance/retention, ICH GCP trained healthcare professionals (HCPs), a generation of gifted young medical students, scientists and researchers who are eager to contribute valuably to the advancement of medical science, availability of trained man power and infrastructure and fairly accommodative regulatory environment at least until now. However, the current scenario tells us a different story.